← boardnext 2027-08next 2029-05
ACAD
ACADIA Pharmaceuticals Inc.distress 0/10 · well-funded / low risk$24.43-2%today-13% from 52w high
Lead: Hyperphagia in Prader-Willi Syndrome · target Oxytocin
Revenue
$268M
Liquidity
$282M
Runway
—
Shares 1y
+2%
Price & events
-11.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.1%
1D
-4.7%
1W
+8.1%
1M
+10.5%
3M
-9.0%
6M
+5.0%
1Y
+34.3%
2Y
+13.8%
5Y
-53.7%
All
Overview
- Market Cap
- $4.18B
- Volume
- 123.49K
- 52 Week Range
- $20.06 – $28.06
- Total Shares
- 171.24M
- Float Shares
- 127.19M
- Short %
- 10.14%
- % Held by Insiders
- 0.32%
- % Held by Institutions
- 98.94%
- RVOL
- 0.07x
- Beta
- 0.80
Pipeline stages · 3 programs
ACP-204
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Carbetocin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pimavanserin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 2 | ACP-211 | Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant | — | recruiting |
| 2028-01 Estimated 50% readout ~2028-03-16 | Phase 2/3 | ACP-204 | Alzheimer's Disease Psychosis | — | recruiting |
| 2028-02 Estimated 50% readout ~2028-03-17 | Phase 2 | ACP-204 | Lewy Body Dementia Psychosis | — | recruiting |
| 2029-02 Estimated 50% readout ~2029-04-17 | Phase 3 | ACP-204 | Lewy Body Dementia Psychosis | — | enrolling by invitation |
| 2029-04 Estimated 50% readout ~2029-06-15 | Phase 3 | ACP-204 | Alzheimer's Disease Psychosis | — | enrolling by invitation |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-05 Estimated 50% readout ~2029-07-15 | Phase 3 | Carbetocin | Hyperphagia in Prader-Willi Syndrome | — | enrolling by invitation |
| 2025-10 | Phase 3 | Carbetocin | Hyperphagia in Prader-Willi Syndrome | 170 | active not recruiting |
| 2025-02-14 | Phase 2/3 | Pimavanserin | Irritability Associated With Autism Spectrum Disorder | 209 | terminated |
Catalyst news & presentations · 2
- end of 2026Guided 40%readoutPhase 2remlifanserin · Planned readout of Phase 2 clinical study.SEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (4)
- DAYBUE STIXTROFINETIDE2025 · Prescription
- DAYBUETROFINETIDE2023 · Prescription
- NUPLAZIDPIMAVANSERIN TARTRATE2018 · Prescription
- NUPLAZIDPIMAVANSERIN TARTRATE2016 · Discontinued
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $33 (+34% upside) · 20 analysts
- 2026-07-21StifelHold
- 2026-07-21BMO CapitalOutperform
- 2026-07-07RBC CapitalOutperform
- 2026-06-30B of A SecuritiesBuy
- 2026-06-29CitigroupBuy
- 2026-06-29Canaccord GenuityBuy
Competitors — Oxytocin
- none identified
Recent news
- 2026-07-21Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate - Yahoo Finance
- 2026-07-21Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate - TradingView
- 2026-07-20Stifel raises Acadia Pharmaceuticals price target on drug potential By Investing.com - Investing.com South Africa
- 2026-07-20Stifel raises Acadia Pharmaceuticals price target on drug potential - Investing.com
- 2026-07-20Stifel raises Acadia Pharmaceuticals price target on drug potential By Investing.com - Investing.com Canada
- 2026-07-20Acadia Pharmaceuticals (ACAD) Receives FDA Fast Track for Remlif - GuruFocus
- 2026-07-20Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis - BioSpace
- 2026-07-20ETFs Investing in ACADIA Pharmaceuticals Inc. Stocks - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.